FB 1992: all centres/groups, trials/strata and treatments

1 Long Beach Veterans' Administration Medical Center, Long Beach, U.S.A. {Olson: MAR-1992}

101 Olson: Randomisation: odd/even; open; Entry MAY-1982 to MAY-1984; Eligibility: acute myocardial infarction; 12h pain; Endpoints: ejection fraction (28[10]h); patency (16[5]d)

1 Streptokinase [0·5MU over 15-20min, iv] + Streptokinase [0·2MU over 2h, iv]; n=28
2 Placebo [200ml over 2·5h, iv]; n=24

2 GISSI, Istituto di Ricerche Farmacologiche "Mario Negri", Milan, Italy {Franzosi, Lesaffre, Maggioni, Tognoni, Van de Werf: MAR-1992}

201 GISSI 1: Randomisation: telephone; open; Entry FEB-1984 to JUN-1985; Eligibility: acute myocardial infarction; 12h pain; Endpoints: mortality (21d, 1yr)

1 Streptokinase [1·5MU over 60min, iv]; n=5860
2 Open Control; n=5852

202 GISSI 2: Randomisation: telephone; open; Entry FEB-1988 to JUL-1989; Eligibility: acute myocardial infarction; 6h pain; Endpoints: combined (mortality (in-hospital) + late CCF (after 4d) + extensive left ventricular damage (pre-discharge echo))

1 Alteplase [100mg over 3h, iv] + Heparin [12500U bd sc]; n=3079
2 Alteplase [100mg over 3h, iv]; n=3103
3 Streptokinase [1·5MU over 30-60min, iv] + Heparin [12500U bd sc]; n=3096
4 Streptokinase [1·5MU over 30-60min, iv]; n=3103

203 ISG: Randomisation: telephone; open; Entry FEB-1988 to JUL-1989; Eligibility: acute myocardial infarction; 6h pain; Endpoints: combined (mortality (in-hospital) + late CCF (after 4d) + extensive left ventricular damage (pre-discharge echo))

1 Alteplase [100mg over 3h, iv] + Heparin [12500U bd sc]; n=5170
2 Alteplase [100mg over 3h, iv]; n=5202
3 Streptokinase [1·5MU over 30-60min, iv]; n=5205
4 Streptokinase [1·5MU over 30-60min, iv] + Heparin [12500U bd sc]; n=5191

3 Freie Universität Berlin, Germany {Bruggemann: MAR-1992}

301 ISAM: Randomisation: blind; Entry MAR-1982 to MAR-1985; Eligibility: acute myocardial infarction; 6h pain; Endpoints: mortality (21d)

1 Streptokinase [1·5MU over 60min, iv]; n=859
2 Control; n=882

4 University of Washington, Seattle, U.S.A. {Kennedy, Maynard: MAR-1992}

401 Western Washington Study: Randomisation: sealed envelopes; open; Entry SEP-1983 to JUL-1986; Eligibility: acute myocardial infarction; 6h pain; Endpoints: mortality (14d); long-term survival; patency; left ventricular function; initial clinical course; measure of infarct size; segmental wall motion

1 Streptokinase [1·5MU over 60min, iv]; n=191
2 Open Control; n=177

5 Royal Devon and Exeter Hospital, Exeter, U.K. {Hall: MAR-1992}

501 Hall: Randomisation: blind; Eligibility: acute myocardial infarction; 6h pain; Endpoints: mortality (1m)

1 Streptokinase [0·6MU bolus, iv]; n=50
2 Placebo; n=50

6 ISIS, Oxford, U.K. {Collins, Parish: MAR-1992}

601 ISIS-2 Pilot Study: Randomisation: telephone; double-blind; Entry JUN-1983 to AUG-1985; Eligibility: acute myocardial infarction; 24h pain; Endpoints: clinical events; mortality

1 Streptokinase [1·5MU over 1h, iv]
2 Control

602 ISIS-2: Randomisation: telephone; double-blind; Entry MAR-1985 to DEC-1987; Eligibility: acute myocardial infarction; 24h pain; Endpoints: mortality (5wk)

1 Control; n=4300
2 Streptokinase [1·5MU over 60min, iv]; n=4300
3 Aspirin [160mg od, po]; n=4295
4 Streptokinase [1·5MU over 60min, iv] + Aspirin [160mg od]; n=4292

603 ISIS-3: Randomisation: telephone; double-blind; Entry SEP-1989 to JAN-1991; Eligibility: acute myocardial infarction; 24h pain

1 Streptokinase [1·5MU over 60min, iv]; n=6887
2 tPA [0·6MU/kg over 4h, iv]; n=6876
3 APSAC [30U over 3min, iv]; n=6880

604 ISIS-3: Randomisation: telephone; double-blind; Entry SEP-1989 to JAN-1991; Eligibility: acute myocardial infarction; 24h pain

1 Streptokinase [1·5MU over 60min, iv]; n=
2 tPA [0·6MU/kg over 4h, iv]; n=
3 APSAC [30U over 3min, iv]; n=
4 Control

7 Green Lane Hospital, Auckland, New Zealand {White: MAR-1992}

701 White: Streptokinase Trial; Randomisation: random list; blind; Entry OCT-1982 to AUG-1986; Eligibility: acute myocardial infarction; 4h pain; Endpoints: ejection fraction (3wk)

1 Streptokinase [1·5MU over 30min, iv]; n=107
2 Control; n=112

702 White: tPA Versus Streptokinase Trial; Randomisation: double-blind double-dummy; Entry FEB-1986 to NOV-1988; Eligibility: acute myocardial infarction; 3h pain; Endpoints: left ventricular function (3wk); mortality

1 Streptokinase [1·5MU over 30min, iv]; n=135
2 tPA [10mg bolus, iv] then tPA [50mg over 60min, iv] then tPA [20mg over 60min, iv] then tPA [20mg over 60min, iv]; n=135

9 Helsinki, Finland {Heikkila: MAR-1992}

901 Heikkila: Eligibility: acute myocardial infarction; Endpoints: ejection fraction (2-4wk) {confounded}

1 Streptokinase [1·8MU over 60min, iv] + Aspirin [100mg od po]; n=72
2 Control; n=55

10 Barcelona, Spain {Figueras: MAR-1992}

1001 Figueras: Eligibility: acute myocardial infarction; 4h pain; Endpoints: mortality (5d)

1 Streptokinase [0·84 MU over 60min, iv]; n=105
2 Control; n=102

11 Karolinska Hospital, Stockholm, Sweden {Rydén: MAR-1992}

1101 Rydén: Randomisation: sealed envelopes; open; Entry FEB-1985 to AUG-1986; Eligibility: acute myocardial infarction; 48h pain; Endpoints: exercise tolerance (3m); symptoms (12m)

1 Streptokinase (iv); n=54
2 Control; n=57

12 EMERA, Argentina {Paolasso, Romero: MAR-1992}

1201 EMERAS: Randomisation: telephone; double-blind; Entry JAN-1988 to JAN-1991; Eligibility: acute myocardial infarction; 24h pain

1 Streptokinase [1·5MU over 60min, iv]; n=?
2 Control; n=?

14 Collen {Collen: MAR-1992}

1401 Collen: Originally identified for FTT, but not eligible; Entry ?

1 (unknown)
2 (unknown)

15 Leuven, Belgium {Simoons, Verstraete, Van de Werf: MAR-1992}

1501 ECSG-1: Randomisation: telephone; double-blind; Entry JAN-1984 to JUN-1985; Eligibility: acute myocardial infarction; 6h pain; Endpoints: patency (75-90min)

1 tPA [0·75mg/kg over 90min, iv]; n=64
2 Control (iv); n=65

1502 ECSG-2: Randomisation: telephone; blind; Entry JUL-1984 to FEB-1985; Eligibility: acute myocardial infarction; 6h pain; Endpoints: patency (75-90min)

1 tPA [0·75mg/kg over 90min, iv]; n=64
2 Streptokinase [1·5MU over 60min, iv]; n=65

1503 ECSG-4: Randomisation: telephone; double-blind; Entry MAY-1986 to NOV-1987; Eligibility: acute myocardial infarction; 5h pain; Endpoints: infarct size; left ventricular function; mortality (in-hospital, 3m)

1 tPA [10mg bolus, iv] then tPA [50mg over 60min, iv] then tPA [40mg over 120min, iv]; n=355
2 Control; n=366

16 Johns Hopkins Hospital, Baltimore, U.S.A. {Guerci: MAR-1992}

1601 Guerci: Double-Chain tPA; Randomisation: random list; double-blind; Entry DEC-1984 to MAR-1987; Eligibility: acute myocardial infarction; 4h pain; Endpoints: patency (mean 5·5h); left ventriculography; 50 patients were entered

1 Double-Chain tPA [40mg over 60min, iv] then Double-Chain tPA [40mg over 120min, iv]; n=50
2 Control

1602 Guerci: Single-Chain tPA; Randomisation: random list; double-blind; Entry DEC-1984 to MAR-1987; Eligibility: acute myocardial infarction; 4h pain; Endpoints: patency (mean 5·5h); left ventriculography

1 Single-Chain tPA [40mg over 60min, iv] then Single-Chain tPA [40mg over 120min, iv]; n=88
2 Control

17 Cleveland, Ohio, U.S.A. {Topol, Woodlief: MAR-1992}

1701 tPA Trial patecy: Randomisation: double-blind; Entry SEP-1985 to FEB-1986; Eligibility: acute myocardial infarction; 6h pain; Endpoints: patency (60, 90, 120min)

1 tPA [0·075mg/kg bolus, iv] then tPA [0·675mg/kg over 60min, iv] then tPA [0·5mg/kg over 120min, iv]; n=75
2 Control (+ Streptokinase (intra-coronary) in the event of an occluded infarct-related coronary); n=25

18 Boston, Massachusetts, U.S.A. {Gold: MAR-1992}

1801 Gold: Randomisation: random list; blind; Eligibility: unstable angina; 12-28h pain; Endpoints: patency (50(19)h); 25 patients were entered

1 tPA [0·75mg/kg over 60min, iv] then tPA [0·5mg/kg over 4h, iv] then tPA [0·5mg/kg over 6h, iv]; n=12
2 Control; n=11

19 ASSET, Nottingham University, U.K. {Skene, Wilcox: MAR-1992}

1901 ASSET: Randomisation: random list; blind; Entry NOV-1986 ff; Eligibility: acute myocardial infarction; 5h pain; Endpoints: mortality (availability of data to be confirmed)

1 tPA [10mg bolus, iv] then tPA [50mg over 60min, iv] then tPA [40mg over 120min, iv]; n=2516
2 Control; n=2495

1902 LATE: Entry ?

1 (unknown)
2 (unknown)

21 TICO, Green Lane Hospital, Auckland, New Zealand {White: MAR-1992}

2101 TICO: Randomisation: random list; blind; Entry FEB-1986 to JUN-1987; Eligibility: acute myocardial infarction; 2·5h pain; Endpoints: left ventricular ejection fraction (21d)

1 tPA [10mg bolus, iv] then tPA [50mg over 60min, iv] then tPA [40mg over 120min, iv]; n=74
2 Control; n=71

22 National Heart Foundation of Australia, Perth, Australia {Thompson: MAR-1992}

2201 Thompson: Randomisation: blind; Entry MAY-1986 to AUG-1987; Eligibility: acute myocardial infarction; 4h pain; Endpoints: left ventriculography (<24h, 28d, 3m); patency (5-7d)

1 tPA [10mg bolus, iv] then tPA [50mg over 60min, iv] then tPA [40mg over 120min, iv]; n=73
2 Control; n=71

24 TPAT, Toronto, Ontario, Canada {Armstrong, Freeman: MAR-1992}

2401 Armstrong: original tPA dose; Randomisation: random list; double-blind; Entry JUN-1987 to JUL-1987; Eligibility: acute myocardial infarction; 3·75h pain; Endpoints: global and regional ejection fraction (9d); 37 patients were entered

1 tPA [0·04MU/kg bolus, iv] then tPA [0·4MU/kg over 60min, iv] then tPA [0·14MU over 60min, iv] then tPA [0·24MU over 8h, iv]
2 Control

2402 Armstrong: revised tPA dose; Randomisation: random list; double-blind; Entry JUL-1987 to DEC-1987; Eligibility: acute myocardial infarction; 3·75h pain; Endpoints: global and regional ejection fraction (9d)

1 tPA [0·04MU/kg bolus, iv] then tPA [0·4MU/kg over 60min, iv] then tPA [0·08MU over 60min, iv] then tPA [0·12MU over 4h, iv]
2 Control

2403 Freeman: Randomisation: double-blind; Entry JUN-1988 to MAR-1990; Eligibility: unstable angina; Endpoints: mortality; revascularisation; MI

1 tPA [0·49MU/kg over 1h, iv] then tPA [0·07MU/kg/h for 9h]
2 Placebo

25 Ann Arbor, Michigan, U.S.A. {Nicklas: MAR-1992}

2501 Nicklas: Randomisation: sealed envelope; blind; Entry MAR-1986 to APR-1987; Eligibility: unstable angina; 7d pain; Endpoints: patency (0, 12-24h)

1 tPA [6mg bolus, iv] then tPA [54mg over 60min, iv] then tPA [40mg over 120min, iv] then tPA [50mg over 5h, iv]; n=20
2 Control; n=20

26 Rhode Island Hospital, Providence, U.S.A. {Williams: MAR-1992}

2601 Williams: Randomisation: sealed envelopes; double-blind; Eligibility: unstable angina; Endpoints: angiography; Entry ?

1 tPA [0·75mg/kg over 60min, iv]; n=23
2 tPA [0·75mg/kg over 60min, total dose 100mg over 6h, iv]; n=22
3 Control; n=22

27 Naples, Italy {Bonaduce: MAR-1992}

2701 Bonaduce: Entry MAR-1988 to NOV-1988; Eligibility: acute myocardial infarction; 8h pain; Endpoints: patency (7-10d); echocardiography (1yr)

1 tPA [10mg bolus, iv] then tPA [50mg over 60min, iv] then tPA [40mg over 2h, iv]; n=12
2 Control; n=12

28 TEAHAT {Herlitz: MAR-1992}

2801 TEAHAT: Entry OCT-1986 to APR-1988; Eligibility: acute myocardial infarction; 2·75h pain; Endpoints: infarct size; left ventricular function

1 tPA [100mg over 3h, iv]; n=177
2 Control; n=175

29 TIMI, Baltimore, U.S.A. {Braunwald, Knatterud: MAR-1992}

2901 TIMI-1: Randomisation: sealed envelope; double-blind; Entry AUG-1984 to FEB-1985; Eligibility: acute myocardial infarction; 7h pain; Endpoints: patency (90min); patency (30, 60min), mortality

1 tPA [40mg over 60min, iv] then tPA [20mg over 60min, iv] then tPA [20mg over 60min, iv]; n=159
2 Streptokinase [1·5MU over 60min, iv]; n=157

2902 TIMI-3: Entry ?

1 (unknown)
2 (unknown)

31 Smith-Kline Beecham, Reigate, U.K. {Julian: MAR-1992}

3101 Julian: Eligibility: acute myocardial infarction; 4h pain; Endpoints: mortality (in-hospital) (data with S.K.B.)

1 APSAC [30U bolus, iv]; n=45
2 Control; n=45

32 Walsgrave Hospital, Coventry, U.K. {Been: MAR-1992}

3201 Been: Eligibility: acute myocardial infarction; 3h pain; Endpoints: patency (90min); mortality (paired sequential design)

1 APSAC [5mg bolus, iv] then APSAC [25mg over 10min, iv]; n=16
2 Control; n=16

33 Smith-Kline-Beecham, Reigate, U.K. {Ikram: MAR-1992}

3301 Ikram: Randomisation: open; Entry FEB-1984 to MAR-1985; Eligibility: acute myocardial infarction; 4h pain; Endpoints: indices of infarct size; mortality (in-hospital, 12m)

1 APSAC [30U bolus, iv]; n=76
2 Control; n=73

34 London Chest Hospital, London, U.K. {Timmis: MAR-1992}

3401 Timmis: Randomisation: double-blind; Eligibility: acute myocardial infarction; 6h pain; Endpoints: patency (3·1(1·2)h, then 90min later)

1 APSAC [30U bolus, iv]; n=16
2 Control; n=13

35 AIMS, London School of Hygiene, London, U.K. {Pocock: MAR-1992}

3501 Pocock: Randomisation: random list; double-blind; Entry SEP-1985 to OCT-1987; Eligibility: acute myocardial infarction; 6h pain; Endpoints: mortality (30d, 1yr) (working data file)

1 APSAC [30U bolus, iv]; n=502
2 Control; n=502

36 Ospedale Maggiore, Milan, Italy {Foresti: MAR-1992}

3601 Foresti: Eligibility: unstable angina; 3h pain; Endpoints: angiography; remission of pain; mortality; Entry ?

1 Urokinase [1·5MU bolus, iv]; n=10
2 Control

37 Genova, Italy {Brunelli: MAR-1992}

3701 Brunelli: Eligibility: acute myocardial infarction; Endpoints: patency (20d); left ventriculography (20d); mortality

1 Urokinase [2MU iv]; n=?
2 Control; n=?

38 Modena, Italy {Zennaro: MAR-1992}

3801 Zennaro: Eligibility: acute myocardial infarction; Endpoints: patency (21d)

1 Urokinase (iv); n=77
2 Control; n=31

42 PAIMS, University of Bologna, Italy {Magnani: MAR-1992}

4201 Magnani: Entry JUL-1986 to JUN-1987; Eligibility: acute myocardial infarction; 3h pain; Endpoints: non-invasive measure of reperfusion; patency (98(41)h for tPA, 95(47)h for Streptokinase); echocardiogaphic assessment of left ventricular function (pre-fibrinolysis, post-fibrinolysis, hospital discharge), mortality

1 tPA [10mg bolus, iv] then tPA [50mg over 60min, iv] then tPA [20mg over 60min, iv] then tPA [20mg over 60min, iv]; n=86
2 Streptokinase [1·5MU over 60min, iv]; n=85

45 Smith-Kline Beecham, France {Brochier: MAR-1992}

4501 IRSII: Randomisation: random list; blind; Entry APR-1985 to SEP-1986; Eligibility: acute myocardial infarction; 4h pain; Endpoints: patency (90min, 24h); mortality

1 APSAC [30U bolus, iv]; n=62
2 Streptokinase [1·5MU over 60min, iv]; n=63

46 Madrid, Spain {Lopez-Sendon: MAR-1992}

4601 Lopez-Sendon: Eligibility: acute myocardial infarction; 6h pain; Endpoints: patency (90min, 24h)

1 APSAC [30U bolus, iv]; n=20
2 Streptokinase [1·5MU over 60min, iv]; n=24

47 Stobhill General Hospital, Glasgow, U.K. {Hillis, Hogg: MAR-1992}

4701 Hillis: Randomisation: double-blind double-dummy; Entry APR-1987 to DEC-1988; Eligibility: acute myocardial infarction; 6h pain; Endpoints: patency (90min, 24h); left ventriculography (24h)

1 APSAC [30U bolus, iv]; n=65
2 Streptokinase [1·5MU over 60min, iv]; n=63

48 University of Utah, Salt Lake City, U.S.A. {Allen, Anderson: MAR-1992}

4801 TEAM-2: Randomisation: double-blind double-dummy; Eligibility: acute myocardial infarction; 4h pain; Endpoints: patency (90-240min, mean 140min; 18-48h, mean 28h)

1 APSAC [30U bolus, iv]; n=188
2 Streptokinase [1·5MU over 60min, iv]; n=182

4802 TEAM-3: Randomisation: double-blind; Eligibility: acute myocardial infarction; 4h pain; Endpoints: patency; left ventricular function; Entry ?

1 APSAC [30U over 5min, iv]; n=162
2 tPA [100mg over 180min, iv]; n=163

49 ENTIM, Smith-Kline-Beecham, France {Bassand: MAR-1992}

4901 Bassand: Randomisation: double-blind double-dummy; Entry MAY-1988 to JUL-1989; Eligibility: acute myocardial infarction; 4h pain; Endpoints: patency (<7d); radionuclide angiography; single-photon emission CT for infarct size and left ventricular function

1 APSAC [30U over 5min, iv]; n=90
2 tPA [100mg over 180min, iv]; n=93

50 TAPS {von Essen: APR-1992}

5001 TAPS: Entry ?

1 (unknown)
2 (unknown)

51 GAUS, Medizinische Klinik II, Kassell, Germany {Neuhaus: MAR-1992}

5101 Neuhaus: Randomisation: telephone; blind; Entry MAR-1986 to FEB-1987; Eligibility: acute myocardial infarction; 6h pain; Endpoints: patency (90min, 24h, >10d)

1 tPA [10mg bolus, iv] then tPA [60mg over 90min, iv]; n=124
2 Urokinase [1·5MU bolus, iv] then Urokinase [1·5MU over 90min, iv]; n=121

52 Medical Clinics of Villingen and Worms, University Hospital Freiburg, Germany {Kasper: MAR-1992}

5201 Kasper: Eligibility: acute myocardial infarction; 6h pain; Endpoints: patency (0, 15, 30, 45, 60, 75, 90min, 24h)

1 PUK [1MU bolus, iv] then PUK [8MU over 60min, iv]; n=24
2 PUK [0·5MU bolus, iv] then PUK [4MU over 60min, iv] + Urokinase [0·2MU bolus, iv]; n=16

54 Ospedale Maggiore, Novara, Italy {Cernigliaro, Rossi: MAR-1992}

5401 USIM: Randomisation: telephone; Entry APR-1986 to SEP-1988; Eligibility: acute myocardial infarction; 4h pain; Endpoints: mortality (16d); non-fatal cardiac events

1 Urokinase [1MU bolus, iv] then Urokinase [1MU over 60min, iv]; n=1128
2 Control; n=1073

5402 USIM-pilot: Randomisation: double blind; Eligibility: acute myocardial infarction; Endpoints: angiography (8-12d); (dose ranging study);

1 Urokinase [0·5MU bolus, iv]
2 Urokinase [1·25MU bolus, iv]
3 Urokinase [2·0MU bolus, iv]

5403 SANSA: Randomisation: sealed envelopes; Eligibility: unstable angina; Endpoints: coronary angiography; clinical events; Entry ?

1 Urokinase [1MU bolus, iv] + Heparin [800-1000U/h for 8d] + Nitroglycerin [10-100µg/min for 8d]
2 Control + Heparin [800-1000U/h for 8d] + Nitroglycerin [10-100µg/min for 8d]
3 Control + Nitroglycerin [10-100µg/min for 8 d]

55 Rigshospitalet, Copenhagen, Denmark {Grande, Munkvad: MAR-1992}

5501 Grande: (found to be part of ASSET)

1 (unknown)
2 (unknown)

56 Freeman Hospital, Newcastle Upon Tyne, U.K. {Adams: MAR-1992}

5601 Adams: Randomisation: double-blind; Entry OCT-1984 to APR-1985; Eligibility: acute myocardial infarction; 3h pain; Endpoints: non-invasive measures of reperfusion; radionuclide ejection fractions (2-6m)

1 APSAC [30U bolus, iv]; n=21
2 Control; n=22

57 Royal Brompton Hospital, London, U.K. {Sigwart: MAR-1992}

5701 Sigwart: Eligibility: acute myocardial infarction; 3h pain; Endpoints: patency (180min)

1 APSAC [30U bolus, iv]; n=51
2 Streptokinase [1·5MU over 60min, iv]; n=49

58 Carnaxide, Portugal {Seabra-Gomes: MAR-1992}

5801 Seabra-Gomes: Eligibility: acute myocardial infarction; 6h pain; Endpoints: patency (0, 15, 30, 45, 60, 75, 90min) (part of 4601)

1 APSAC [30U bolus, iv]; n=5
2 Streptokinase [1·5MU over 60min, iv]; n=5

59 APSAC Research Group, Lyon, France {Leizorovicz: MAR-1992}

5901 Leizorovicz: Randomisation: double-blind; Eligibility: acute myocardial infarction; 6h pain; Endpoints: patency (0, 15, 30, 45, 60, 90min) (dose-ranging study)

1 APSAC [15U bolus, iv]; n=9
2 APSAC [20U bolus, iv]; n=9
3 APSAC [25U bolus, iv]; n=11
4 APSAC [30U bolus, iv]; n=10
5 Control; n=11

60 Lucknow, India {Saran: MAR-1992}

6001 Saran: Entry NOV-1985 to SEP-1987; Eligibility: unstable angina

1 Streptokinase [1·5MU over 30min, iv]; n=24
2 Control; n=24

61 TAMI, Duke University Medical Center, Durham, U.S.A. {Califf, Lee: MAR-1992}

6101 TAMI-5: Randomisation: telephone; open; Entry APR-1988 to MAY-1989; Eligibility: acute myocardial infarction; 6h pain; Endpoints: patency (90min, pre-discharge); global left ventricular function; combined adverse events (ordered as death, stroke, reinfarction, recurrent ischaemia or heart failure); regional left ventricular function; bleeding event rates

1 (tPA [6mg bolus, iv] then tPA [54mg over 60min, iv] then tPA [40mg over 2h]) + (Urokinase [1·5MU bolus, iv] then Urokinase[1·5MU over 90min, iv])
2 tPA [6mg bolus, iv] then tPA [54mg over 60min, iv] then tPA [40mg over 2h, iv]
3 Urokinase [1·5MU bolus, iv] then Urokinase [1·5MU over 90min, iv]

6102 TAMI-6: Eligibility: acute myocardial infarction; 24h pain; Endpoints: patency (mean 36h)

1 tPA [100mg over 3h, iv]; n=?
2 Control; n=?

6103 GUSTO: Entry ?

1 (unknown)
2 (unknown)

63 Maastricht, Netherlands {Bar, Verheugt: MAR-1992}

6301 UNASEM: Randomisation: double-blind; Eligibility: unstable angina; myocardial infarction; persistent angina; PTCA; CABG; Endpoints: mortality; Entry ?

1 APSAC (iv); n=65
2 Control; n=61

64 SHAPE, Whittington Hospital, London, U.K. {Patterson: MAR-1992}

6401 Patterson: Randomisation: double-blind; Eligibility: acute myocardial infarction; Endpoints: functional assessment (1yr); mortality (3:1 randomisation, numbers not in strict ratio)

1 tPA [100mg iv]; n=435
2 Control; n=159

65 Grünenthal, Germany {Vermeer, Bösl: MAR-1992}

6501 SAT: Randomisation: blind; Entry: JUL-1988 to JUN-1989; Eligibility: acute myocardial infarction; Endpoints: Haemostatic variables

1 Prourokinase [20mg bolus + 60mg over 1h, iv]
2 Alteplase [10mg bolus + 50mg over 1h + 40mg over 2h, iv]

6502 SUTAMI: Randomisation: double-blind; Eligibility: acute myocardial infarction; Endpoints: patency; mortality; Entry ?

1 Prourokinase [20mg bolus + 60mg over 1h, iv]
2 Urokinase [1·5MU bolus + 1·5MU over 1h, iv]

6503 PRIMI: Randomisation: double blind; double-dummy; Entry OCT-1986 to MAY-1988; Eligibility: acute myocardial infarction; 4h pain; Endpoints: patency (90min); patency (60min); rate of reocclusion within 24-36h; changes in the haemostatic system

1 PUK [20mg bolus, iv] then PUK [60mg over 60min, iv]; n=198
2 Streptokinase [1·5MU over 60min, iv]; n=203

67 STAMP Study Group, Tubingen, Germany {Karsch: MAR-1992}

6701 Karsch: Eligibility: acute myocardial infarction; 6h pain; Endpoints: patency (14d); mortality (in-hospital)

1 PUK [4·5MU, iv] (?mode) + Urokinase [0·25MU, iv] (?mode); n=?
2 Streptokinase [1·5MU, iv]; n=?

69 Kawai, Japan {Kawai: APR-1992}

6901 Japanese Multi centre study for PPA: Entry ?

1 (unknown)
2 (unknown)

70 Thoraxcenter, Rotterdam, Netherlands {Van den Brand: MAR-1992}

7001 Van den Brand: Entry NOV-1987 to APR-1989; Eligibility: unstable angina; Endpoints: angiography (10h)

1 tPA [100mg over 3h, iv]; n=19
2 Control; n=17

71 Tokai University Medical School, Japan {Kanemoto: MAR-1992}

7101 Japanese ms of tPA vs UK: Randomisation: double-blind; Eligibility: acute MI; Endpoints: Patency; Ejection fraction; Entry ?

1 tPA [33mg over 1h, iv]
2 tPA [50mg over 1h, iv]
3 Urokinase [960000U over 1h, iv]

72 Linkoping, Sweden {Karlsson: MAR-1992}

7201 TRIC: Randomisation: double-blind; Eligibility: unstable angina; Endpoints: Clinical events; mortality; revascularisation; Entry ?

1 tPA [1mg/Kg body weight, iv, (max 100mg)]
2 Placebo [iv]

73 Royal Victoria Hospital, Belfast, Ireland {Roberts: MAR-1992}

7301 Roberts: Randomisation: double-blind; Eligibility: unstable angina; Endpoints: mortality; revascularisation; Entry ?

1 tPA [100mg over 3h, iv]
2 Placebo

75 Policlinico San Matteo {Ardissino: APR-1992}

7501 Ardissino: Randomisation: double-blind; Eligibility: unstable angina; Endpoints: angiography; Entry ?

1 tPA [10mg bolus + 50mg over 1h + 40mg over 4h, iv] n=12
2 Placebo n=12

80 SUNY, Stony Brook {:}

8001 VLAY: Randomisation: unknown; Eligibility: acute MI, Pain < 6h; Endpoints: Echocardiography; mortality; Entry ?

1 Streptokinase [1MU over 1h, iv] + Metoprolol
2 Control

98 Test (Pamela) {:}

9801 Pamela: Randomisation: Dodgy; Entry N/A

1 Drug
2 No Drug

[End of document, updated to 1 September 2000]